

## Effects of suberogorgin and its derivatives on learning and memory in mice

PENG Wen-Duo, XU Shi-Bo, PENG Xun<sup>1</sup> (Pharmacology Laboratory, Department of Biology, Sun Yat-Sen University, Guangzhou 510275, China)

**KEY WORDS** suberogorgin; *N*-suberogorgamide-*N*-*N*-dicyclohexyl urea; *N*-cyclohexyl suberogorgamide; scopolamine; cycloheximide; learning; memory; cholinesterase inhibitors

**AIM:** To study the relationship between the effects of suberogorgin (Sub) and its derivatives on memory and their anti-acetylcholinesterase (AChE) actions. **METHODS:** The step-down latency (SDL) and the escape latency (EL) of mice were determined at the same time in a passive avoidance task after Sub, *N*-suberogorgamide-*N*-*N*-dicyclohexyl urea (Sub-DU), or *N*-cyclohexyl suberogorgamide (*N*-CS) was injected ip. The AChE activities in brain hemogenates were determined with colorimetry.

**RESULTS:** Sub 1.9, Sub-DU 3.0, or physostigmine (Phys) 0.15 mg · kg<sup>-1</sup> obviously lengthened the SDL by 195 %, 271 %, and 210 %, and shortened the EL by 56 %, 61 %, and 33 %, and the two formers inhibited the brain AChE activities by 17 % and 19 %, respectively in aging (3-4 months) mice. These actions were decreased in a dose-dependent manner when Sub or Sub-DU was increased to 2.9-4.3 or 4.5-6.7 mg · kg<sup>-1</sup> respectively. Sub 1.9, Sub-DU 2.0, and Phys 0.15 mg · kg<sup>-1</sup> also lengthened the SDL by 187 %, 209 %, and 152 %, and shortened the EL by 52 %, 62 %, and 57 %, respectively in aged (12-14 months) mice. Sub 1.3-1.9, Sub-DU 0.9-2.0, or Phys 0.15 mg · kg<sup>-1</sup> reversed the cycloheximide- or scopolamine-induced disruptions of memory retention. No obvious effect of *N*-CS on the acquisition of memory and the AChE activity in mice was observed. **CONCLUSION:** The improvements of Sub and Sub-DU on memory were chiefly related to their anti-AChE actions.


Suberogorgin (Sub) was isolated from

<sup>1</sup>Now in Cancer Hospital, School of Medicine, Shantou University, Shantou 515031, China.

Received 1994-09-05


Accepted 1995-05-30

*Gorgoniae suberogorgia* sp from South China Sea<sup>[1]</sup>. Its inhibition on acetylcholinesterase (AChE) was not very strong<sup>[2]</sup>. *N*-Suberogorgamide-*N*-*N*-dicyclohexyl urea (Sub-DU) and *N*-cyclohexyl suberogorgamide (*N*-CS) were synthesized. The LD<sub>50</sub> of Sub, Sub-DU, and *N*-CS iv were 23.6, 35.8, and 84.0 mg · kg<sup>-1</sup>, respectively. The anti-AChE action of Sub-DU was stronger than that of Sub, but that of *N*-CS was very weak. Since some AChE inhibitors can treat the senile dementia<sup>[3]</sup>, the effects of Sub, Sub-DU, and *N*-CS on the memory in normal mice and experimental memory-disrupted mice were studied.




R = OH

Sub



*N*-CS



Sub-DU

### MATERIALS AND METHODS

Sub, spectrum pure, was isolated by Department of Chemistry, Sun Yat-Sen University; Sub-DU and *N*-CS, spectrum pure, were synthesized by our laboratory; Physostigmine salicylate (Phys) (Research grade, Serva); Scopolamine hydrobromide (Scop) (Injectio, Guangzhou Qiao Guang Pharmaceutical Factory, China); Cycloheximide (Cyc) (BR, Sigma); Acetylthiocholine iodide (ATCh) (>99 % pure, Fluka); 5,5'-dithio 2,2'-dinitrobenzoic acid

(DTNB) (BR, Shanghai Institute of Biochemistry, Chinese Academy of Sciences); Sodium dodecyl sulphate (SDS) (>99 % pure, BDH).

Aging (3-4 months) NIH mice ( $n = 15 - 28$ ) weighing  $22.8 \pm 1.8$  g of either sex and aged (12-14 months) mice ( $n = 23$ ) weighing  $40 \pm 5$  g of ♂ were bred in our laboratory.

**Passive avoidance task** A wooden box (30 cm × 30 cm × 20 cm) which was separated into 4 equal chambers by black plastic planks. Each chamber had a platform in the right corner. Copper nets (30 V) were laid on the floor. Passive avoidance task was tested<sup>(3)</sup>. For disruption of memory retention, mice were injected sc with Cyc  $150.0 \text{ mg} \cdot \text{kg}^{-1}$  or Scop  $2.0 \text{ mg} \cdot \text{kg}^{-1}$ , and then ip with test drugs or saline after training. Retention tests were performed 24 or 4 h after Cyc or Scop respectively. The step-down latency (SDL) and the escape latency (EL) of mice were determined. The data were analyzed by ANOVA after 2 longest and 2 shortest latencies in each group were eliminated.

**Determination of AChE activity** In the experiments of acquisition of memory, 10 mice of each group were randomly sampled, and injected ip with Sub, Sub-DU, N-CS, or saline. After 30 min, their brains were homogenized at 0 °C. The AChE activity in hemogenates was determined colorimetrically<sup>(2)</sup>.

**RESULTS**

**Memory** Thirty min after aging mice were injected ip with Sub 0.6 - 2.9, Sub-DU 0.9 - 4.5, or Phys 0.10 - 0.15  $\text{mg} \cdot \text{kg}^{-1}$ , their SDL were obviously lengthened and EL were shortened (Tab 1). No obvious effect of N-CS 2.0 - 6.8  $\text{mg} \cdot \text{kg}^{-1}$  on SDL and EL was observed. In aged mice, Sub 1.3 - 1.9, Sub-DU 1.3 - 2.0, or Phys 0.10 - 0.15  $\text{mg} \cdot \text{kg}^{-1}$  lengthened the SDL and shortened the EL (Tab 1).

**Reversal of Cyc-induced disruption of memory retention** Cyc shortened the SDL and lengthened the EL ( $P < 0.01$ ). Cyc + Sub 0.9 - 1.9, Cyc + Sub-DU 0.9 - 2.0, and Cyc + Phys 0.15  $\text{mg} \cdot \text{kg}^{-1}$  lengthened the SDL and shortened the EL, compared with Cyc + NS; Cyc + Sub 1.9, Cyc + Sub-DU 1.3 - 2.0  $\text{mg} \cdot \text{kg}^{-1}$  still lengthened the SDL and shortened the EL, compared with saline (Tab 2).

**Reversal of Scop-induced transient disruption of short-term memory retention** Scop shortened the SDL ( $P < 0.01$ ) and lengthened the EL ( $P < 0.05$ ). Scop + Sub 1.3 - 1.9, Scop + Sub-DU 1.3 - 2.0, and Scop + Phys 0.15  $\text{mg} \cdot \text{kg}^{-1}$  lengthened

**Tab 1. Effects of suberogorin (Sub), N-suberogorgamide-N-N-dicyclohexyl urea (Sub-DU), N-cyclohexyl suberogorgamide (N-CS), and physostigmine (Phys) on acquisition of memory of aging (3-4 months,  $n = 28$ ) and aged (12-14 months,  $n = 23$ ) mice in a passive avoidance task before and 30 min after medication.**  
 $\bar{x} \pm s$ . \* $P > 0.05$ , <sup>b</sup> $P < 0.05$ , <sup>c</sup> $P < 0.01$  vs 0  $\text{mg} \cdot \text{kg}^{-1}$ .

	$\text{mg} \cdot \text{kg}^{-1}$	Step-down latency/s		Escape latency/s	
		Before	After	Before	After
In aging mice					
	0	13 ± 6	21 ± 10	26 ± 12	18 ± 9
Sub	0.6	15 ± 5 <sup>a</sup>	32 ± 16 <sup>b</sup>	22 ± 13 <sup>a</sup>	13 ± 6 <sup>b</sup>
	0.9	14 ± 5 <sup>a</sup>	44 ± 26 <sup>c</sup>	23 ± 10 <sup>a</sup>	10 ± 6 <sup>c</sup>
	1.3	12 ± 4 <sup>a</sup>	59 ± 33 <sup>c</sup>	25 ± 15 <sup>a</sup>	8 ± 4 <sup>c</sup>
	1.9	12 ± 6 <sup>a</sup>	62 ± 41 <sup>c</sup>	24 ± 14 <sup>a</sup>	8 ± 5 <sup>c</sup>
	2.9	17 ± 9 <sup>a</sup>	54 ± 42 <sup>c</sup>	28 ± 15 <sup>a</sup>	9 ± 7 <sup>c</sup>
Sub-DU	4.3	15 ± 8 <sup>a</sup>	22 ± 15 <sup>a</sup>	28 ± 18 <sup>a</sup>	16 ± 11 <sup>a</sup>
	0.9	15 ± 6 <sup>a</sup>	33 ± 12 <sup>b</sup>	25 ± 13 <sup>a</sup>	11 ± 6 <sup>c</sup>
	1.3	13 ± 3 <sup>a</sup>	57 ± 25 <sup>c</sup>	26 ± 15 <sup>a</sup>	10 ± 4 <sup>c</sup>
	2.0	13 ± 6 <sup>a</sup>	65 ± 44 <sup>c</sup>	26 ± 12 <sup>a</sup>	8 ± 5 <sup>c</sup>
	3.0	16 ± 7 <sup>a</sup>	78 ± 56 <sup>c</sup>	29 ± 19 <sup>a</sup>	7 ± 3 <sup>c</sup>
N-CS	4.5	14 ± 6 <sup>a</sup>	42 ± 24 <sup>c</sup>	27 ± 16 <sup>a</sup>	12 ± 9 <sup>b</sup>
	6.7	14 ± 7 <sup>a</sup>	27 ± 18 <sup>a</sup>	22 ± 11 <sup>a</sup>	21 ± 15 <sup>a</sup>
	2.0	13 ± 4 <sup>a</sup>	19 ± 7 <sup>a</sup>	26 ± 11 <sup>a</sup>	16 ± 7 <sup>a</sup>
	3.0	15 ± 8 <sup>a</sup>	24 ± 13 <sup>a</sup>	23 ± 13 <sup>a</sup>	18 ± 10 <sup>a</sup>
	4.5	15 ± 6 <sup>a</sup>	25 ± 11 <sup>a</sup>	20 ± 12 <sup>a</sup>	15 ± 11 <sup>a</sup>
Phys	6.8	16 ± 6 <sup>a</sup>	20 ± 10 <sup>a</sup>	27 ± 14 <sup>a</sup>	20 ± 12 <sup>a</sup>
	0.10	13 ± 7 <sup>a</sup>	49 ± 30 <sup>c</sup>	30 ± 20 <sup>a</sup>	17 ± 7 <sup>a</sup>
	0.15	14 ± 3 <sup>a</sup>	65 ± 46 <sup>c</sup>	28 ± 10 <sup>a</sup>	12 ± 6 <sup>b</sup>
	0.22	15 ± 7 <sup>a</sup>	41 ± 34 <sup>c</sup>	24 ± 16 <sup>a</sup>	13 ± 8 <sup>b</sup>
In aged mice					
	0	10 ± 6	23 ± 16	28 ± 17	21 ± 11
Sub	1.3	12 ± 8 <sup>a</sup>	50 ± 29 <sup>c</sup>	29 ± 14 <sup>a</sup>	13 ± 6 <sup>c</sup>
	1.9	10 ± 5 <sup>a</sup>	66 ± 38 <sup>c</sup>	25 ± 12 <sup>a</sup>	10 ± 6 <sup>c</sup>
Sub-DU	1.3	11 ± 8 <sup>a</sup>	57 ± 32 <sup>c</sup>	26 ± 13 <sup>a</sup>	11 ± 8 <sup>c</sup>
	2.0	11 ± 7 <sup>a</sup>	71 ± 48 <sup>c</sup>	30 ± 14 <sup>a</sup>	8 ± 4 <sup>c</sup>
Phys	0.10	10 ± 4 <sup>a</sup>	52 ± 29 <sup>c</sup>	27 ± 18 <sup>a</sup>	15 ± 8 <sup>b</sup>
	0.15	12 ± 6 <sup>a</sup>	58 ± 38 <sup>c</sup>	28 ± 15 <sup>a</sup>	9 ± 3 <sup>c</sup>

the SDL and shortened the EL, compared with Scop + NS; Scop + Sub-DU 1.3 - 2.0, Scop + Phys 0.15  $\text{mg} \cdot \text{kg}^{-1}$  also lengthened the SDL and shortened the EL, compared with saline (Tab 2).

**Inhibition on AChE of brain hemogenates** Compared with saline group, Sub 0.9, 1.9, and 4.3  $\text{mg} \cdot \text{kg}^{-1}$  decreased the AChE activities to  $90 \pm 9$  % ( $P < 0.05$ ),  $83 \pm 7$  % ( $P < 0.01$ ), and  $70 \pm 9$  % ( $P < 0.01$ ), respectively; Sub-DU 1.3, 3.0, and 6.7  $\text{mg} \cdot \text{kg}^{-1}$  inhibited the AChE activities to  $88 \pm 6$  % ( $P < 0.05$ ),  $81 \pm 10$  % ( $P < 0.01$ ), and  $73 \pm 8$  % ( $P < 0.01$ ), respectively. No inhibition of N-CS 2.0, 4.5, and 6.8  $\text{mg} \cdot \text{kg}^{-1}$  on

**Tab 2. Reversal of cycloheximide (Cyc)- or scopolamine (Scop)-induced disruption of memory retention of aging mice (*n* = 25 or 15 respectively) in a passive avoidance task.  $\bar{x} \pm s$ . <sup>a</sup>*P* > 0.05, <sup>b</sup>*P* < 0.05, <sup>c</sup>*P* < 0.01 vs NS + NS; <sup>d</sup>*P* > 0.05, <sup>e</sup>*P* < 0.05, <sup>f</sup>*P* < 0.01 vs Cyc + NS or Scop + NS.**

	mg · kg <sup>-1</sup>	Step-down latency/s	Escape latency/s
NS + NS		30 ± 19	10 ± 4
Cyc + NS		11 ± 7 <sup>c</sup>	17 ± 10 <sup>c</sup>
Cyc + Sub	150.0 + 0.9	25 ± 16 <sup>df</sup>	10 ± 6 <sup>df</sup>
	150.0 + 1.3	41 ± 18 <sup>df</sup>	9 ± 6 <sup>df</sup>
	150.0 + 1.9	50 ± 29 <sup>df</sup>	7 ± 5 <sup>df</sup>
Cyc + Sub-DU	150.0 + 0.9	33 ± 21 <sup>df</sup>	8 ± 5 <sup>df</sup>
	150.0 + 1.3	54 ± 40 <sup>df</sup>	8 ± 3 <sup>df</sup>
	150.0 + 2.0	60 ± 38 <sup>df</sup>	6 ± 5 <sup>df</sup>
Cyc + Phys	150.00 + 0.10	35 ± 16 <sup>df</sup>	15 ± 10 <sup>od</sup>
	150.00 + 0.15	49 ± 22 <sup>df</sup>	10 ± 6 <sup>ae</sup>
NS + NS		38 ± 23	12 ± 7
Scop + NS		12 ± 19 <sup>c</sup>	18 ± 16 <sup>b</sup>
Scop + Sub	2.0 + 0.9	18 ± 19 <sup>od</sup>	15 ± 8 <sup>df</sup>
	2.0 + 1.3	28 ± 19 <sup>df</sup>	10 ± 11 <sup>oe</sup>
	2.0 + 1.9	26 ± 23 <sup>df</sup>	10 ± 9 <sup>oe</sup>
Scop + Sub-DU	2.0 + 0.9	22 ± 18 <sup>be</sup>	10 ± 14 <sup>df</sup>
	2.0 + 1.3	34 ± 29 <sup>df</sup>	8 ± 8 <sup>df</sup>
	2.0 + 2.0	39 ± 43 <sup>df</sup>	8 ± 5 <sup>df</sup>
Scop + Phys	2.00 + 0.10	20 ± 22 <sup>bd</sup>	12 ± 11 <sup>df</sup>
	2.00 + 0.15	31 ± 17 <sup>df</sup>	9 ± 4 <sup>df</sup>

AChE was seen.

**DISCUSSION**

The methods of determining the SDL and EL at the same time can eliminate the interferences induced by the unspecific effects of test drugs<sup>[3]</sup>. The reversals of Sub and Sub-DU on Scop-induced disruption of memory retention indicated that Sub and Sub-DU might act on the memory process specifically.

The memory improvements of Sub and Sub-DU were reduced when they were increased to 2.9 - 4.3 and 4.5 - 6.7 mg · kg<sup>-1</sup> respectively. These were related to the blockade of nerve induced by too much ACh<sup>[3]</sup>. N-CS, which inhibition on AChE was not obvious, had no effect on memory. The above observations, together with the anti-AChE actions of Sub and Sub-DU, showed that the improvements of Sub and Sub-DU on memory were chiefly related to their inhibitions on AChE. In addition, the results that Sub and Sub-DU reversed the Cyc-

induced disruption of memory retention indicated that the anti-AChE action was not the sole mechanism of their memory-improvements.

Irregulation of central cholinergic function induce a disturbance of learning and memory in aged mammals<sup>[4]</sup>. Alzheimer's disease is related to the defect of cholinergic nerve conduction<sup>[3]</sup>. The memory-improvements of Sub and Sub-DU in aged mice suggested that both might be investigated as anti-senile-dementia drugs.

**REFERENCES**

- 1 Niu LW, Dai JB, Wan ZL, Liang DC, Wu ZD, Yao ZN, et al. Molecular structure and absolute configuration of suberogargin. *Sci Sin (B)* 1986; 29: 40-9.
- 2 Xu SB, Peng WD, Hu YT, Wang YF. Excitant effect of sodium suberogargin on isolated rabbit ileum. *Acta Pharmacol Sin* 1992; 13: 459-63.
- 3 Zhu XD, Tang XC. Improvement of impaired memory in mice by huperzine A and huperzine B. *Acta Pharmacol Sin* 1988; 9: 492-7.
- 4 Soncrant TT, Holloway HW, Greig NH, Rapport SI. Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in aging and aged Fischer 344 rats. *Brain Res* 1989; 487: 289-94.

215-218

**柳珊瑚酸及其衍生物对小鼠学习和记忆的影响**

彭汶铎, 许实波, 彭 逸<sup>1</sup>  
(中山大学生物系药理室, 广州 510275, 中国)

R 965.1  
R 964

**关键词** 柳珊瑚酸; N-柳珊瑚酰胺-N,N-二环己基脲; N-环己基柳珊瑚酰胺; 东莨菪碱; 环己酰亚胺; 学习; 记忆; 胆碱酯酶抑制剂 衍生物

**目的:** 研究柳珊瑚酸(Sub)、N-柳珊瑚酰胺-N,N-二环己基脲(Sub-DU), N-环己基柳珊瑚酰胺(N-CS)在影响记忆与抗胆碱酯酶(AChE)作用间的关系. **方法:** 在被动回避操作装置上测定小鼠ip Sub或其衍生物后的跳台潜伏期(SDL)和逃避潜伏期(EL); 比色法测定AChE活力. **结果:** Sub 1.9, Sub-DU 3.0和Phys 0.15 mg · kg<sup>-1</sup>分别使成年小鼠的SDL延长195%, 271%和210%, EL缩短56%, 61%和33%; 前二者尚同时使小鼠全脑匀浆AChE活力各降低17%和19%. 大于上述剂量时, Sub和Sub-DU对SDL和EL的作用依剂量地减弱. Sub 1.9, Sub-DU 2.0和Phys

0.15 mg·kg<sup>-1</sup>还可使老年小鼠的 SDL 各延长 187 %, 209 % 和 152 %, EL 各缩短 52 %, 62 % 和 57 %。三药尚明显改善由环己酰亚胺或东莨

菪碱产生的记忆保持损害。N-CS 无上述作用。  
结论: Sub 和 Sub-DU 对记忆的改善作用与其抗 AChE 有关。

BIBLID: ISSN 0253-9756

Acta Pharmacologica Sinica 中国药理学报

1996 May; 17 (3): 218 - 220

## Effects of calcitonin injected into various brain areas on pain threshold and Ca<sup>2+</sup> in rats

ZHAO Xiao-Ping, WANG Shao<sup>1</sup>, XIA Ying-Hong

(Department of Physiology, Norman Bethune University of Medical Sciences, Changchun 130021, China)

**KEY WORDS** pain threshold; calcitonin; cerebral ventricles; periaqueductal gray; calcium

**AIM:** To study the effects of calcitonin (Cal) injected into different brain areas on pain threshold. **METHODS:** The analgesic effects of Cal were investigated in rats by the tail-flick test.

**RESULTS:** Cal injected into lateral cerebral ventricle (LCV) or periaqueductal gray (PAG) increased obviously the pain threshold to 49 ± 22 % or to 68 ± 12 % (*P* < 0.01), respectively. When PAG was blocked with lidocaine, the analgesic effect of Cal injected into LCV was lowered 41 ± 9 %. Cal injected into habenula (Hab) decreased the pain threshold to -30 ± 5 % (*P* < 0.01). **CONCLUSION:** Cal in different rat brain areas induced different effects on pain responses: analgesia or hyperalgesia, and showed that PAG played an important role in the analgesic effect induced by Cal, and the changing of pain threshold was mediated by the Ca<sup>2+</sup> in brain.

Calcitonin (Cal) showed an analgesic action which is involved in the binding of opioid receptors in brain<sup>[1]</sup>. Periaqueductal gray (PAG) and Habenula (Hab) are the key relays in the realizing of the analgesic action of morphine and acupuncture<sup>[2,3]</sup>. The Ca<sup>2+</sup> in CNS antagonizes the analgesic actions of both morphine and acupuncture<sup>[4,5]</sup>. What is about the role of Cal and what is

the relationship between Cal analgesia and Ca<sup>2+</sup>? To assay this problem will benefit the comprehension of the mechanism of Cal analgesia.

### METHODS

Wistar rats of either sex (*n* = 76) weighing 220 ± 30 g were anesthetized with chloral hydrate 0.4 g·kg<sup>-1</sup>. Stainless steel guide cannula (OD 0.7 mm, ID 0.4 mm) were inserted into unilateral ventricle, bilateral of PAG, and Hab according to the atlas of König & Klippel and the cannula were anchored with dental cement to the skull. A stainless steel cannula (OD 0.4 mm) was in the guide cannula for injection of drugs. After 5 d, experiments were carried out in a quiet room at 20.0 ± 0.5 °C. The pain threshold were measured by the tail-flick test with a radiant heat sustained for 4 - 5 s. The basal pain threshold was the average of 3 trials before the drug was used.

Cal was injected into LCV 1 μL·min<sup>-1</sup>, 5 μL; bilateral PAG 1 μL·min<sup>-1</sup>, 2 μL/side; bilateral Hab 0.25 μL·min<sup>-1</sup>, 0.5 μL/side.

Injection sites were marked by injecting 2 % pontamine sky blue. The brains were stored in 10 % formalin for at least 5 d. Cannula tip placements were verified from 40 μm coronal sections. Rats were included if the target areas were correct.

The Cal was from Tou You Corporation, Japan, 10 kU·L<sup>-1</sup> injection. Other drugs were dissolved in saline.

### RESULTS

**1 Analgesic effect of Cal injected into LCV, PAG and Hab** Five minutes after Cal injected into LCV 12.5 - 50 μU in 5 μL the pain threshold was raised, reached the maximum at 20 min, and recovered to the basal level after 1 h. The analgesic

<sup>1</sup> Correspondence to Prof WANG Shao

Received 1994-06-28

Accepted 1995-09-08